{"name":"Agomab Spain S.L.","slug":"agomab-spain-s-l","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AGMB-129","genericName":"AGMB-129","slug":"agmb-129","indication":"Treatment of various cancers","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AGMB-447","genericName":"AGMB-447","slug":"agmb-447","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AGMB-129","genericName":"AGMB-129","slug":"agmb-129","phase":"phase_2","mechanism":"AGMB-129 is an anti-CD47 monoclonal antibody.","indications":["Treatment of various cancers"],"catalyst":""},{"name":"AGMB-447","genericName":"AGMB-447","slug":"agmb-447","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPdWZYcUhEVnUxS2ttTXlhLWZwNFF2czFEMGxpNHlKalowWWhicklVUEgxdFdsUzJrWXAyYzFlbkdvbG1ZU0x5SWxza293ZzZqNmFPTmN4ZXRyaVk0dDBZc0M0RTYtTEd3REI0YUlHUzdRWF9WZ1dPbVA5LTRGdTBWNXJxX0s4Ym1SR2FUc3JOMFhDYnhyc0VpRUEzd09zbE9BcFZuQXUxcjhvVWFidUp5bnN0TW5pUQ?oc=5","date":"2024-06-07","type":"regulatory","source":"Pharmacy Times","summary":"FDA Grants Orphan Drug Designation to AGMB-447 for Idiopathic Pulmonary Fibrosis - Pharmacy Times","headline":"FDA Grants Orphan Drug Designation to AGMB-447 for Idiopathic Pulmonary Fibrosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOdEczMWw3N2ZRNzVDNHExNHBQd25GS1p5emtXaFNBTjBZX0pTUEZHMmg1d214OHA3ZXBKcG5JaXE3amNnYnFfX2pOeDk5TURncW9yTTBxWE1BWGcxMHFLYWFNZUZScDNLdGxlUTRyNE5RSkNKQzJvdGZFdHBENl94aHlCSmxNNDRoRG1SY0ZDeHU?oc=5","date":"2024-05-02","type":"pipeline","source":"Yahoo Finance","summary":"Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena Pharmaceuticals, Pfizer, Abivax, Janssen, Celgene, Eli Lilly","headline":"Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developin","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}